Aquestive Therapeutics (AQST) Research & Development (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Research & Development of $4.2 million for Q1 2026, down 21.58% year-over-year from $5.4 million in Q1 2025, and up 31.54% quarter-over-quarter from $3.2 million in Q4 2025.
Aquestive Therapeutics (AQST) Research & Development (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.
- In Q1 2026, Research & Development fell 21.58% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $16.0 million (down 18.64% YoY), while the FY2025 annual figure was $17.2 million, down 15.23% from the prior year.
- Research & Development for Q1 2026 stood at $4.2 million, up from $3.2 million in the prior quarter.
- The five-year high for Research & Development was $5.9 million in Q1 2024, with the low at $2.9 million in Q4 2023.
- The 5-year median for Research & Development is $4.2 million (2026), against an average of $4.3 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development soared 70.26% in 2024, then plunged 35.0% in 2025.
- Aquestive Therapeutics' Research & Development stood at $4.3 million in 2022, then plunged by 32.49% to $2.9 million in 2023, then surged by 70.26% to $4.9 million in 2024, then slumped by 35.0% to $3.2 million in 2025, then surged by 31.54% to $4.2 million in 2026.
- Business Quant data shows AQST's Research & Development at $4.2 million in Q1 2026, $3.2 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Aquestive Therapeutics | 553.72 Mn | 553.72 Mn | 9.80 Mn | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.96 Mn |
| Mar 31, 2026 | 4.20 Mn |
| Dec 31, 2025 | 3.20 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | 4.11 Mn |
| Mar 31, 2025 | 5.36 Mn |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 5.27 Mn |
| Jun 30, 2024 | 4.16 Mn |
| Mar 31, 2024 | 5.93 Mn |
| Dec 31, 2023 | 2.89 Mn |
| Sep 30, 2023 | 3.20 Mn |
| Jun 30, 2023 | 3.47 Mn |
| Mar 31, 2023 | 3.55 Mn |
| Dec 31, 2022 | 4.28 Mn |
| Sep 30, 2022 | 3.23 Mn |
| Jun 30, 2022 | 5.20 Mn |
| Mar 31, 2022 | 4.77 Mn |
| Dec 31, 2021 | 4.40 Mn |
| Sep 30, 2021 | 4.73 Mn |